Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif ™) using B cell receptor repertoire analysis

A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif ™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized that high-throughput B-cell receptor (BCR) repertoire analysis could be used to predict and monitor ADA development. To study this we analyzed 228 peripheral blood samples from 68 longitudinally fol lowed patients starting on interferon beta-1a. Our results show that whole blood BCR analysis does not reflect, and does not predict ADA development in MS patients treated with interferon beta-1a.

Source: Journal of Neuroimmunology - July 12, 2022 Category: Allergy & Immunology Authors: Linda van der Weele, Sabrina Pollastro, Barbera D.C. van Schaik, Antoine H.C. van Kampen, Ilse T.G. Niewold, Taco W. Kuijpers, Clemens Warnke, Poul Erik H. Jensen, Daniel Kramer, Malin Ryner, Christina Hermanrud, Pierre D önnes, Marc Pallardy, Sebastian Source Type: research